Cargando…

Lenvatinib Induces Immunogenic Cell Death and Triggers Toll-Like Receptor-3/4 Ligands in Hepatocellular Carcinoma

PURPOSE: Immunogenic cell death (ICD) is a cell death modality that plays a vital role in anticancer therapy. In this study, we investigated whether lenvatinib induces ICD in hepatocellular carcinoma and how it affects cancer cell behavior. PATIENTS AND METHODS: Hepatoma cells were treated with 0.5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Cheng, Yang, Zhang-Fu, Sun, Bao-Ye, Yi, Yong, Wang, Zheng, Zhou, Jian, Fan, Jia, Gan, Wei, Ren, Ning, Qiu, Shuang-Jian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149778/ https://www.ncbi.nlm.nih.gov/pubmed/37138764 http://dx.doi.org/10.2147/JHC.S401639

Ejemplares similares

Lenvatinib plus anti-PD-1 therapy represents a feasible conversion resection strategy for patients with initially unresectable hepatocellular carcinoma: A retrospective study
por: Yi, Yong, et al.
Publicado: (2022)

Toll-Like Receptors, Their Ligands, and Atherosclerosis
por: Hodgkinson, Conrad P., et al.
Publicado: (2011)

Infiltration of T Cells and Programmed Cell Death Ligand 1-expressing Macrophages as a Potential Predictor of Lenvatinib Response in Hepatocellular Carcinoma
por: Sung, Pil Soo, et al.
Publicado: (2020)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Effectiveness and safety of lenvatinib plus anti‐programmed death‐1 antibodies in patients with hepatocellular carcinoma: A real‐world cohort study
por: Xu, Ming‐Hao, et al.
Publicado: (2023)

Lenvatinib Plus Camrelizumab versus Lenvatinib Monotherapy as Post-Progression Treatment for Advanced Hepatocellular Carcinoma: A Short-Term Prognostic Study
por: Wei, Fuqun, et al.
Publicado: (2021)

Different Mechanisms of Action of Regorafenib and Lenvatinib on Toll-Like Receptor-Signaling Pathways in Human Hepatoma Cell Lines
por: Sasaki, Reina, et al.
Publicado: (2020)

Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma
por: He, Min-Ke, et al.
Publicado: (2021)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
por: Zhao, Shu, et al.
Publicado: (2022)

Lenvatinib Combined with Anti-PD-1 Antibodies Plus Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
por: Wu, Jia-Yi, et al.
Publicado: (2021)

The oncolytic peptide LTX-315 triggers immunogenic cell death
por: Zhou, H, et al.
Publicado: (2016)

Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis
por: Funderburg, Nicholas, et al.
Publicado: (2008)

Endogenous toll-like receptor ligands and their biological significance
por: Yu, Li, et al.
Publicado: (2010)

Lenvatinib Plus Camrelizumab vs. Lenvatinib Monotherapy as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Cohort Study
por: Li, Qi, et al.
Publicado: (2022)

Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
por: Zhang, Menglong, et al.
Publicado: (2022)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
por: Hatanaka, Takeshi, et al.
Publicado: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
por: Lee, Matthew Man Pok, et al.
Publicado: (2023)

Circulating immune index predicting the prognosis of patients with hepatocellular carcinoma treated with lenvatinib and immunotherapy
por: Guo, De-Zhen, et al.
Publicado: (2023)

Feasibility and Tolerability of Lenvatinib, Plus PD-1 Blockades for Patients with Unresectable Hepatocellular Carcinoma: A Retrospective Exploratory Study
por: Jia, Meng, et al.
Publicado: (2022)

Determinants of Divergent Adaptive Immune Responses after Airway Sensitization with Ligands of Toll-Like Receptor 5 or Toll-Like Receptor 9
por: Lee, Linda M., et al.
Publicado: (2016)

Efficacy and safety of lenvatinib for preventing tumor recurrence after liver transplantation in hepatocellular carcinoma beyond the Milan criteria
por: Guo, De-Zhen, et al.
Publicado: (2022)

Toll-like receptor ligands regulate the migratory pattern of leukocytes
por: Nieto, J C, et al.
Publicado: (2010)

Characterization of Chicken Thrombocyte Responses to Toll-Like Receptor Ligands
por: St. Paul, Michael, et al.
Publicado: (2012)

A new “sweet” ligand for Toll-like receptor 4
por: Deierborg, Tomas, et al.
Publicado: (2015)

Activation of Innate Immunity by Bacterial Ligands of Toll-Like Receptors
por: Akhmatova, Nelli K., et al.
Publicado: (2014)

Trial watch: Toll-like receptor ligands in cancer therapy
por: Le Naour, Julie, et al.
Publicado: (2023)

Clinical outcomes of lenvatinib plus transarterial chemoembolization with or without programmed death receptor-1 inhibitors in unresectable hepatocellular carcinoma
por: Wang, Yan-Yu, et al.
Publicado: (2023)

Combination of Vitamin C and Lenvatinib potentiates antitumor effects in hepatocellular carcinoma cells in vitro
por: Wang, Xinyue, et al.
Publicado: (2023)

Lenvatinib for the treatment of unresectable hepatocellular carcinoma: evidence to date
por: Personeni, Nicola, et al.
Publicado: (2019)

Therapeutic efficacy of lenvatinib in nonviral unresectable hepatocellular carcinoma
por: Tomonari, Tetsu, et al.
Publicado: (2021)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
por: Amioka, Kei, et al.
Publicado: (2022)

Nephrotic Syndrome Induced by Lenvatinib Treatment for Hepatocellular Carcinoma
por: Prasoppokakorn, Thaninee, et al.
Publicado: (2022)

Lenvatinib applicability in the therapeutic strategy of patients with hepatocellular carcinoma
por: Merle, Philippe
Publicado: (2023)

Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
por: Sho, Takuya, et al.
Publicado: (2021)

Lenvatinib in combination with transarterial chemoembolization for treatment of unresectable hepatocellular carcinoma (uHCC): a retrospective controlled study
por: Fu, Zhigang, et al.
Publicado: (2021)

Programmed cell death‐ligand 1 expression in hepatocellular carcinoma and its correlation with clinicopathological characteristics
por: Mou, Haibo, et al.
Publicado: (2021)

Efficacy and safety of hepatic arterial infusion chemotherapy combined with programmed cell death protein-1 antibody and lenvatinib for advanced hepatocellular carcinoma
por: Xu, Yongkang, et al.
Publicado: (2022)

Analyzing molecular typing and clinical application of immunogenic cell death-related genes in hepatocellular carcinoma
por: Lin, Cai-Feng, et al.
Publicado: (2023)

Toll-like receptors 2 expression in mediastinal lymph node of patients with sarcoidosis
por: Chen, Xianqiu, et al.
Publicado: (2020)

In silico study of ligand binding site of toll-like receptor 5
por: Savar, Nastaran Sadat, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_od8sp6de7jj1qhaf74b2e5ldub